We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ECOPETROL:BVCEcopetrol SA Analysis

Data as of 2026-05-15 - not real-time

COP 2,530.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Ecopetrol trades at 2,530 COP, sitting just above its 20‑day SMA (2,488.75) but below the 50‑day SMA (2,555.4), indicating a mixed short‑term bias. The RSI of 51.7 and a bullish MACD histogram (+3.86) suggest modest momentum, while the price remains bounded by a support level around 2,325 COP and resistance near 2,620 COP. Volume has been decreasing and 30‑day volatility is high at 48%, though the beta of –0.27 points to low systematic risk.
Fundamentally, the stock appears undervalued with a trailing P/E of 10.15 versus an industry average of 21.46 and a P/B of 1.24. Dividend yield is attractive at 4.87% with a payout ratio of 43%, but earnings are under pressure – revenue fell 8.7% and profit margin is only 7.5%. The balance sheet is strained: debt‑to‑equity is near 100% and operating cash flow is flat, while Moody’s downgraded the global rating to Ba2 with a negative outlook. Analysts rate the stock as a “hold” and consensus price targets (median 2,200 COP) imply a downside of roughly 9.8%.
Overall, the valuation and dividend appeal are tempered by weak cash generation, high leverage, and deteriorating credit sentiment. Technicals give a slight short‑term upside, but liquidity concerns and credit risk dominate the longer horizon, leading to a hold stance in the near term and a sell recommendation for the longer term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD histogram indicating short‑term momentum
  • Undervalued valuation metrics (P/E 10.15 vs industry 21.46)
  • Decreasing volume and high volatility raising liquidity concerns

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong dividend yield but limited cash flow generation
  • High debt‑to‑equity ratio and recent Moody’s downgrade
  • Analyst consensus targets below current price suggesting downside

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Sustained earnings contraction and negative revenue growth
  • Elevated leverage with minimal operating cash flow
  • Credit rating downgrade to Ba2 with a negative outlook

Key Metrics & Analysis

Financial Health

Revenue Growth-8.70%
Profit Margin7.51%
P/E Ratio10.2
Debt/Equity99.96
P/B Ratio1.2
Industry P/E21.5

Technical Analysis

TrendNeutral
RSI51.7
SupportCOP 2,325.00
ResistanceCOP 2,620.00
MA 20COP 2,488.75
MA 50COP 2,555.40
MA 200COP 2,082.75
MACDBullish
VolumeDecreasing
Fear & Greed Index87.91

Valuation

Target PriceCOP 2,282.43
Upside/Downside-9.79%
GradeUndervalued
TypeValue
Dividend Yield4.87%

Risk Assessment

Beta-0.27
Volatility48.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.